Anja Reuter

1.2k total citations · 1 hit paper
31 papers, 469 citations indexed

About

Anja Reuter is a scholar working on Infectious Diseases, Epidemiology and Surgery. According to data from OpenAlex, Anja Reuter has authored 31 papers receiving a total of 469 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Infectious Diseases, 21 papers in Epidemiology and 6 papers in Surgery. Recurrent topics in Anja Reuter's work include Tuberculosis Research and Epidemiology (28 papers), Pneumocystis jirovecii pneumonia detection and treatment (16 papers) and Pneumonia and Respiratory Infections (8 papers). Anja Reuter is often cited by papers focused on Tuberculosis Research and Epidemiology (28 papers), Pneumocystis jirovecii pneumonia detection and treatment (16 papers) and Pneumonia and Respiratory Infections (8 papers). Anja Reuter collaborates with scholars based in South Africa, United States and France. Anja Reuter's co-authors include Jennifer Furin, Jennifer Hughes, Helen Cox, Erika Mohr-Holland, Johnny Daniels, James A. Seddon, Vivian Cox, Francesca Conradie, Megan Murray and Shaheed Vally Omar and has published in prestigious journals such as The Lancet, American Journal of Respiratory and Critical Care Medicine and Journal of Clinical Microbiology.

In The Last Decade

Anja Reuter

28 papers receiving 457 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Multidrug-resistant tuberculosis

2024 70 citations Keertan Dheda, Fuad Mirzayev et al. Nature Reviews Disease Primers profile →

Peers

Countries citing papers authored by Anja Reuter

Since Specialization

Citations

This map shows the geographic impact of Anja Reuter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anja Reuter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anja Reuter more than expected).

Fields of papers citing papers by Anja Reuter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anja Reuter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anja Reuter. The network helps show where Anja Reuter may publish in the future.

Co-authorship network of co-authors of Anja Reuter

This figure shows the co-authorship network connecting the top 25 collaborators of Anja Reuter. A scholar is included among the top collaborators of Anja Reuter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anja Reuter. Anja Reuter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The time is now: making the case for compassionate use/pre-approval access to new TB drugs 2025 ·PubMed ·Anja Reuter, Jonathan Stillo, (unknown), Irene Motta, Giovanni Battista Migliori, (unknown), (unknown), Pauline Howell, Lorenzo Guglielmetti, Agnes Gebhard, Tom Decroo, Lia D’Ambrosio, Jennifer Furin	0
2	Multidrug-resistant tuberculosis breakdown → 2024 ·Nature Reviews Disease Primers ·Keertan Dheda, Fuad Mirzayev, Daniela María Cirillo, Zarir Udwadia, Kelly E. Dooley, Kwok Chiu Chang, Shaheed Vally Omar, Anja Reuter, Tahlia Perumal, C. Robert Horsburgh, Megan Murray, Christoph Lange	70
3	Effect of compensatory evolution in the emergence and transmission of rifampicin-resistant Mycobacterium tuberculosis in Cape Town, South Africa: a genomic epidemiology study 2023 ·The Lancet Microbe ·Galo A. Goig, Fabrizio Menardo, (unknown), Anzaan Dippenaar, Elizabeth M. Streicher, Johnny Daniels, Anja Reuter, Sònia Borrell, Miriam Reinhard, (unknown), Christian Beisel, Robin M. Warren, Helen Cox, Sébastien Gagneux	20
4	Treatment of Infection as a Core Strategy to Prevent Rifampicin-Resistant/Multidrug-Resistant Tuberculosis 2023 ·Pathogens ·Anja Reuter, Jennifer Furin	1
5	Making the Case for All-Oral, Shorter Regimens for Children with Drug-Resistant Tuberculosis 2023 ·American Journal of Respiratory and Critical Care Medicine ·(unknown), Andrea T. Cruz, (unknown), Anthony J. Garcia‐Prats, Alexander Kay, Anja Reuter, H. Simon Schaaf, James A. Seddon, Sangeeta Sharma, Jeffrey R. Starke, (unknown), Rina Triasih, Jennifer Furin	5
6	Tuberculosis Diagnosis and Preventive Monotherapy Among Children and Adolescents Exposed to Rifampicin-Resistant Tuberculosis in the Household 2023 ·Open Forum Infectious Diseases ·(unknown), Helen Cox, (unknown), Johnny Daniels, Shaheed Mathee, (unknown), (unknown), (unknown), Vanessa Mudaly, Erika Mohr-Holland, Petros Isaakidis, Colin Pfaff, Jennifer Furin, Anja Reuter	3
7	Causes of loss to follow-up from drug-resistant TB treatment in Khayelitsha, South Africa 2022 ·Public Health Action ·(unknown), (unknown), (unknown), Erika Mohr-Holland, Johnny Daniels, (unknown), (unknown), Vera Scott, (unknown), Colin Pfaff, Anja Reuter, Jennifer Furin	3
8	Early mortality during rifampicin-resistant TB treatment 2022 ·The International Journal of Tuberculosis and Lung Disease ·Erika Mohr-Holland, Johnny Daniels, Anja Reuter, Carly A. Rodriguez, Carole D. Mitnick, (unknown), Vivian Cox, Jennifer Furin, Helen Cox	6
9	Potential contribution of HIV during first-line tuberculosis treatment to subsequent rifampicin-monoresistant tuberculosis and acquired tuberculosis drug resistance in South Africa: a retrospective molecular epidemiology study 2021 ·The Lancet Microbe ·Helen Cox, (unknown), Galo A. Goig, Mark P. Nicol, Fabrizio Menardo, Anzaan Dippenaar, Erika Mohr-Holland, Johnny Daniels, Patrick Cudahy, Sònia Borrell, Miriam Reinhard, (unknown), Christian Beisel, Anja Reuter, Jennifer Furin, Sébastien Gagneux, Robin M. Warren	13
10	Tuberculosis preventive therapy for children and adolescents: an emergency response to the COVID-19 pandemic 2021 ·The Lancet Child & Adolescent Health ·Erika Mohr-Holland, (unknown), (unknown), (unknown), Shaheed Mathee, (unknown), Vanessa Mudaly, Colin Pfaff, Petros Isaakidis, Jennifer Furin, Anja Reuter	11
11	Outcomes of Children Born to Pregnant Women With Drug-resistant Tuberculosis Treated With Novel Drugs in Khayelitsha, South Africa: A Report of Five Patients 2021 ·The Pediatric Infectious Disease Journal ·(unknown), Erika Mohr-Holland, Johnny Daniels, Jennifer Furin, Marian Loveday, Vanessa Mudaly, Anja Reuter	10
12	Treatment Outcomes 24 Months after Initiating Short Bedaquiline- or Injectable-Containing Rifampicin-Resistant Tuberculosis Treatment Regimens: A Retrospective Cohort Study in South Africa 2021 ·SSRN Electronic Journal ·Norbert Ndjeka, Jonathon R. Campbell, Graeme Meintjes, Gary Maartens, H. Simon Schaaf, Jennifer Hughes, Xavier Padanilam, Anja Reuter, (unknown), Farzana Ismail, Martin Enwerem, (unknown), Francesca Conradie, Kogieleum Naidoo, Dick Menzies	1
13	Injectable-free regimens containing bedaquiline, delamanid, or both for adolescents with rifampicin-resistant tuberculosis in Khayelitsha, South Africa 2020 ·EClinicalMedicine ·Erika Mohr-Holland, Anja Reuter, Jennifer Furin, Anthony J. Garcia‐Prats, Virginia De Azevedo, Vanessa Mudaly, (unknown), (unknown), Petros Isaakidis, Jennifer Hughes	16
14	Preventing tuberculosis in children: A global health emergency 2020 ·Paediatric Respiratory Reviews ·Anja Reuter, James A. Seddon, Ben J. Marais, Jennifer Furin	11
15	Responding to SARS-CoV-2 in South Africa: what can we learn from drug-resistant tuberculosis? 2020 ·European Respiratory Journal ·Norbert Ndjeka, Francesca Conradie, Graeme Meintjes, Anja Reuter, Jennifer Hughes, Xavier Padanilam, Nazir Ismail, (unknown), Iqbal Master, (unknown), Julian te Riele, Martin Enwerem, Hannetjie Ferreira, Gary Maartens	3
16	Barriers and solutions to finding rifampicin-resistant tuberculosis cases in older children and adolescents 2019 ·Public Health Action ·Erika Mohr-Holland, (unknown), Anja Reuter, (unknown), Jeremy Hill, (unknown), James A. Seddon, Petros Isaakidis, Jennifer Furin, (unknown)	1
17	Challenges and controversies in childhood tuberculosis 2019 ·The Lancet ·Anja Reuter, Jennifer Hughes, Jennifer Furin	57
18	Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa 2018 ·European Respiratory Journal ·Erika Mohr-Holland, Jennifer Hughes, Anja Reuter, (unknown), Gabriella Ferlazzo, Johnny Daniels, Virginia De Azevedo, (unknown), Sarah Jane Steele, Amir Shroufi, S. Adè, Natavan Alikhanova, Guido Benedetti, Jeffrey K. Edwards, Helen Cox, Jennifer Furin, Petros Isaakidis	27
19	The devil we know: is the use of injectable agents for the treatment of MDR-TB justified? 2017 ·The International Journal of Tuberculosis and Lung Disease ·Anja Reuter, Phumeza Tisile, Dalene von Delft, Helen Cox, Vivian Cox, Lucica Diţiu, Anthony J. Garcia‐Prats, Serena P. Koenig, Erica Lessem, Ruvandhi R. Nathavitharana, James A. Seddon, Jonathan Stillo, Arne von Delft, Jennifer Furin	50
20	Initiation of antiretroviral therapy at high CD4+ cell counts is associated with positive treatment outcomes 2015 ·AIDS ·Viviane D. Lima, Anja Reuter, P. Richard Harrigan, Lillian Lourenço, (unknown), Mark Hull, Lauren J MacKenzie, Silvia Guillemi, Robert S. Hogg, Rolando Barrios, Julio Montaner	28

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact